bringing ultra-orphan drugs to marke
Ultra-orphan drugs and NICE
  • September 22, 2017
  • Steve Bradshaw

March 2017 saw the National Institute for Health and Care Excellence (NICE) board, with input from the NHS England Specialised Services Commissioning Committee, agree to a change that will have a substantial impact on both patients and the companies bringing ultra-orphan drugs to market. In this article we consider what is going to change and […]